Determinants and Functional Significance of Myocardial Perfusion Reserve in Severe Aortic Stenosis

OBJECTIVES: The purpose of this study was to assess the functional significance of cardiac magnetic resonance (CMR) measures of left ventricular (LV) remodeling and myocardial perfusion reserve (MPR) in patients with severe aortic stenosis (AS), without obstructive coronary artery disease. Measures of stenosis severity do not correlate well with exercise intolerance in AS. LV remodeling in AS is associated with myocardial fibrosis and impaired MPR. The functional significance and determinants of MPR in AS are unclear.

METHODS: Forty-six patients with isolated severe AS were prospectively studied before aortic valve replacement. The following investigations were undertaken: cardiopulmonary exercise testing to measure aerobic exercise capacity (peak VO(2)); CMR to assess left ventricular mass index (LVMI), myocardial fibrosis with late gadolinium enhancement (LGE), myocardial blood flow (MBF), and MPR; and transthoracic echocardiography to assess stenosis severity and diastolic function.

RESULTS: Peak VO(2) was associated with sex (β = -0.41), age (β = -0.32), MPR (β = 0.45), resting MBF (β = -0.53), and septal transmitral flow velocity to annular velocity ratio (E/E’) (β = -0.34), but not with LVMI, LGE, or echocardiographic measures of AS severity. On stepwise regression analysis, only MPR was independently associated with age- and sex-corrected peak VO(2) (β = 0.46, p = 0.001). MPR was also inversely related to New York Heart Association functional class (p = 0.001). Univariate associations with MPR were sex (β = 0.38, p = 0.02), septal E/E’ (β = -0.30, p = 0.03), peak aortic valve velocity (β = -0.34, p = 0.02), LVMI (β = -0.51, p < 0.001), and LGE category (β = -0.46, p = 0.002). On multivariate analysis, LVMI and LGE were independently associated with MPR.

CONCLUSIONS: CMR-quantified MPR is independently associated with aerobic exercise capacity in severe AS. LV remodeling appears to be a more important determinant of impaired MPR than stenosis severity per se. Further work is required to determine how CMR assessment of MPR can aid clinical management of patients with AS.

PMID: 22340825

Intima Media Thickness Variability (IMTV) and its Association With Cerebrovascular Events: A Novel Marker of Carotid Atherosclerosis?

OBJECTIVES: Increased intima-media thickness (IMT) is an early marker of atherosclerotic disease and several prospective studies have demonstrated that IMT is a strong predictor of cerebrovascular complications. In this paper we propose a  novel method to assess IMT, called “intima media thickness variability” (IMTV) and evaluate its relationship with the development of cerebrovascular events.

METHODS: The study was approved by the local IRB. Twenty consecutive patients underwent ultrasound analysis of the carotid arteries (mean age 68 years; age range 59-81 years). The IMT and IMTV of the 40 carotid vessels was assessed. Bland–Altman statistics were employed to measure the inter-observer variability, and ROC analysis was used to assess the association with cerebrovascular events.

RESULTS: In all cases the ROC area under the curve was higher for IMTV than IMT. There was a statistical significant association between IMTV and cerebrovascular events (P=0.018), but no relationship between IMT and events. The results for inter-observer variability showed a systematic error between 0.04 mm and 0.08 mm. In the Person Rho correlation analysis in no case a statistical association between IMT and symptoms was detected whereas in 2 cases (observer 1 and observer 2), a statistically significant association between IMTV and symptoms was found.

CONCLUSIONS: Data of this preliminary study suggest that IMTV may represent a powerful method to assess carotid atherosclerotic disease with a significant association to cerebrovascular events.

PMID:

Non-Invasive Assessment of Atherosclerotic Coronary Lesion Length Using Multidetector Computed Tomography Angiography: Comparison to Quantitative Coronary Angiography

OBJECTIVES: Multidetector computed tomography angiography (CTA) provides information on plaque extent and stenosis in the coronary wall. More accurate lesion assessment may be feasible with CTA as compared to invasive coronary angiography (ICA).

METHODS: Accordingly, lesion length assessment was compared between ICA and CTA in patients referred for CTA who underwent subsequent percutaneous coronary intervention (PCI).

RESULTS: 89 patients clinically referred for CTA were subsequently referred for ICA and PCI. On CTA, lesion length was measured from the proximal to the distal shoulder of the plaque. Quantitative coronary angiography (QCA) was performed to analyze lesion length. Stent length was recorded for each lesion. In total, 119 lesions were retrospectively identified. Mean lesion length on CTA was 21.4 ± 8.4 mm and on QCA 12.6 ± 6.1 mm. Mean stent length deployed was 17.4 ± 5.3 mm. Lesion length on CTA was significantly longer than on QCA (difference 8.8 ± 6.7 mm, P < 0.001). Moreover, lesion length visualized on CTA was also significantly longer than mean stent length (CTA lesion length-stent length was 4.2 ± 8.7 mm, P < 0.001).

CONCLUSIONS: Lesion length assessed by CTA is longer than that assessed by ICA. Possibly, CTA provides more accurate lesion length assessment than ICA and may facilitate improved guidance of percutaneous treatment of coronary lesions.

PMID: 22271073

3-Dimensional Aortic Annular Assessment by Multidetector Computed Tomography Predicts Moderate or Severe Paravalvular Regurgitation After Transcatheter Aortic Valve Replacement

OBJECTIVES: This study sought to analyze multidetector computed tomography (MDCT) 3-dimensional aortic annular dimensions for the prediction of paravalvular aortic regurgitation (PAR) following transcatheter aortic valve replacement (TAVR). Moderate or severe PAR after TAVR is associated with increased morbidity and mortality.

METHODS: A total of 109 consecutive patients underwent MDCT pre-TAVR with a balloon expandable aortic valve. Differences between transcatheter heart valve (THV) size and MDCT measures of annular size (mean diameter, area, and circumference) were analyzed concerning prediction of PAR. Patients with THV malposition (n = 7) were excluded. In 50 patients, MDCT was repeated after TAVR to assess THV eccentricity (1 – short diameter/long diameter) and expansion (MDCT measured THV area/nominal THV area).

RESULTS: Moderate or severe PAR (13 of 102) was associated with THV undersizing (THV diameter – mean diameter = –0.7 ± 1.4 mm vs. 0.9 ± 1.8 mm for trivial to mild PAR, p < 0.01). The difference between THV size and MDCT annular size was predictive of PAR (mean diameter: area under the curve [AUC]: 0.81, 95% confidence interval [CI]: 0.68 to 0.88; area: AUC: 0.80, 95% CI: 0.65 to 0.90; circumference: AUC: 0.76, 95% CI: 0.59 to 0.91). Annular eccentricity was not associated with PAR (AUC: 0.58, 95% CI: 0.46 to 0.75). We found that 35.3% (36 of 102) and 45.1% (46 of 102) of THVs were undersized relative to the MDCT mean diameter and area, respectively. THV oversizing relative to the annular area was not associated with THV eccentricity or underexpansion (oversized vs. undersized THVs; expansion: 102.7 ± 5.3% vs. 106.1 ± 5.6%, p = 0.03; eccentricity: median: 1.7% [interquartile range: 1.4% to 3.0%] vs. 1.7% [interquartile range: 1.1% to 2.7%], p = 0.28).

CONCLUSIONS: MDCT-derived 3-dimensional aortic annular measurements are predictive of moderate or severe PAR following TAVR. Oversizing of THVs may reduce the risk of moderate or severe PAR.

PMID:

Impact of Statin Therapy on Plaque Characteristics as Assessed by Serial OCT, Grayscale and Integrated Backscatter-IVUS

OBJECTIVES: The purpose of this study was to evaluate the effect of statin treatment on coronary plaque composition and morphology by optical coherence tomography (OCT), grayscale and integrated backscatter (IB) intravascular ultrasound (IVUS) imaging. Although previous studies have demonstrated that statins substantially improve cardiac mortality, their precise effect on the lipid content and fibrous cap thickness of atherosclerotic coronary lesions is less clear. While IVUS lacks the spatial resolution to accurately assess fibrous cap thickness, OCT lacks the penetration of IVUS. We used a combination of OCT, grayscale and IB-IVUS to comprehensively assess the impact of pitavastatin on plaque characteristics.

METHODS: Prospective serial OCT, grayscale and IB-IVUS of nontarget lesions was performed in 42 stable angina patients undergoing elective coronary intervention. Of these, 26 received 4 mg pitavastatin after the baseline study; 16 subjects who refused statin treatment were followed with dietary modification alone. Follow-up imaging was performed after a median interval of 9 months.

RESULTS: Grayscale IVUS revealed that in the statin-treated patients, percent plaque volume index was significantly reduced over time (48.5 ± 10.4%, 42.0 ± 11.1%; p = 0.033), whereas no change was observed in the diet-only patients (48.7 ± 10.4%, 50.4 ± 11.8%; p = NS). IB-IVUS identified significant reductions in the percentage lipid volume index over time (34.9 ± 12.2%, 28.2 ± 7.5%; p = 0.020); no change was observed in the diet-treated group (31.0 ± 10.7%, 33.8 ± 12.4%; p = NS). While OCT demonstrated a significant increase in fibrous cap thickness (140 ± 42 μm, 189 ± 46 μm; p = 0.001), such changes were not observed in the diet-only group (140 ± 35 μm, 142 ± 36 μm; p = NS). Differences in the changes in the percentage lipid volume index (-6.8 ± 8.0% vs. 2.8 ± 9.9%, p = 0.031) and fibrous cap thickness (52 ± 32 μm vs. 2 ± 22 μm, p < 0.001) over time between the pitavastatin and diet groups were highly significant.

CONCLUSIONS: Statin treatment induces favorable plaque morphologic changes with an increase in fibrous cap thickness, and decreases in both percentage plaque and lipid volume indexes.

PMID: 22340823

Diagnostic Accuracy of Computed Tomography Coronary Angiography According to Pre-Test Probability of Coronary Artery Disease and Severity of Coronary Arterial Calcification The CORE-64 (Coronary Artery Evaluation Using 64-Row Multidetector Computed Tomography Angiography) International Multicenter Study

OBJECTIVES: The purpose of this study was to assess the impact of patient population characteristics on accuracy by computed tomography angiography (CTA) to detect obstructive coronary artery disease (CAD). The ability of CTA to exclude obstructive CAD in patients of different pre-test probabilities and in presence of coronary calcification remains uncertain.

METHODS: For the CORE-64 (Coronary Artery Evaluation Using 64-Row Multidetector Computed Tomography Angiography) study, 371 patients underwent CTA and cardiac catheterization for the detection of obstructive CAD, defined as ≥50% luminal stenosis by quantitative coronary angiography (QCA). This analysis includes 80 initially excluded patients with a calcium score ≥600. Area under the receiver-operating characteristic curve (AUC) was used to evaluate CTA diagnostic accuracy compared to QCA in patients according to calcium score and pre-test probability of CAD.

RESULTS: Analysis of patient-based quantitative CTA accuracy revealed an AUC of 0.93 (95% confidence interval [CI]: 0.90 to 0.95). The AUC remained 0.93 (95% CI: 0.90 to 0.96) after excluding patients with known CAD but decreased to 0.81 (95% CI: 0.71 to 0.89) in patients with calcium score ≥600 (p = 0.077). While AUCs were similar (0.93, 0.92, and 0.93, respectively) for patients with intermediate, high pre-test probability for CAD, and known CAD, negative predictive values were different: 0.90, 0.83, and 0.50, respectively. Negative predictive values decreased from 0.93 to 0.75 for patients with calcium score <100 or ≥100, respectively (p = 0.053).

CONCLUSIONS: Both pre-test probability for CAD and coronary calcium scoring should be considered before using CTA for excluding obstructive CAD. For that purpose, CTA is less effective in patients with calcium score ≥600 and in patients with a high pre-test probability for obstructive CAD.

PMID: 22261160

Prognostic Value of Myocardial Viability by Delayed-Enhanced Magnetic Resonance in Patients With Coronary Artery Disease and Low Ejection Fraction: Impact of Revascularization Therapy

OBJECTIVES: The purpose of this study was to evaluate the impact of myocardial viability assessment by delayed-enhanced cardiac magnetic resonance (DE-CMR) and of revascularization therapy on survival in patients with coronary artery disease (CAD) and low ejection fraction (EF). Prior studies have shown that DE-CMR predicts recovery of left ventricular (LV) dysfunction after revascularization.

METHODS: The authors prospectively evaluated survival of 144 consecutive patients (130 males, age 65 ± 11 years) with CAD and LV dysfunction (EF: 24 ± 7%) undergoing DE-CMR. Eighty-six patients underwent complete revascularization of dysfunctional myocardium (79 coronary artery bypass grafting, 7 percutaneous coronary intervention), whereas 58 patients remained under medical treatment.

RESULTS: Over the 3-year median follow-up, 49 patients died. Three-year survival was significantly worse in medically treated patients with dysfunctional viable than with nonviable myocardium (48% vs. 77% survival, p = 0.02). By contrast, in revascularized patients, survival was similar whether myocardium was viable or not (88% and 71% survival, respectively, p = NS). Hazard of death of viable myocardium remaining under medical treatment versus complete revascularization was 4.56 (95% confidence interval [CI]: 1.93 to 10.8). Cox multivariate analysis indicated that interaction of revascularization and viability provided significant additional value (chi-square test = 13.1, p = 0.004) to baseline predictors of survival (New York Heart Association functional class, wall motion score, and peripheral artery disease). More importantly, in 43 pairs of propensity score–matched patients, hazard of death (hazard ratio: 2.5 [95% CI: 1.1 to 6.1], p = 0.02) remained significantly higher for medically treated patients rather than for those with fully revascularized viable myocardium.

CONCLUSIONS: Without revascularization, presence of dysfunctional viable myocardium by DE-CMR is an independent predictor of mortality in patients with ischemic LV dysfunction. This observation may be useful for pre-operative selection of patients for revascularization.

PMID:

The Diagnosis of Hypertrophic Cardiomyopathy by Cardiovascular Magnetic Resonance

Hypertrophic cardiomyopathy (HCM) is the most common genetic disease of the heart. HCM is characterized by a wide range of clinical expression, ranging from asymptomatic mutation carriers to sudden cardiac death as the first manifestation of the disease. Over 1000 mutations have been identified, classically in genes encoding sarcomeric proteins. Noninvasive imaging is central to the diagnosis of HCM and cardiovascular magnetic resonance (CMR) is increasingly used to characterize morphologic, functional and tissue abnormalities associated with HCM. The purpose of this review is to provide an overview of the clinical, pathological and imaging features relevant to understanding the diagnosis of HCM. The early and overt phenotypic expression of disease that may be identified by CMR is reviewed. Diastolic dysfunction may be an early marker of the disease, present in mutation carriers prior to the development of left ventricular hypertrophy (LVH). Late gadolinium enhancement by CMR is present in approximately 60% of HCM patients with LVH and may provide novel information regarding risk stratification in HCM. It is likely that integrating genetic advances with enhanced phenotypic characterization of HCM with novel CMR techniques will importantly improve our understanding of this complex disease.

PMID:

Prediction of Coronary Artery Calcium Progression in Individuals With Low Framingham Risk Score

OBJECTIVES: This study sought to determine whether novel markers not involving ionizing radiation could predict coronary artery calcium (CAC) progression in a low-risk population. Increase in CAC scores over time (CAC progression) improves prediction of coronary heart disease (CHD) events. Due to radiation exposure, CAC measurement represents an undesirable method for repeated risk assessment, particularly in individuals with low predicted risk (Framingham Risk Score [FRS]

METHODS: From 6,814 participants in MESA (Multi-Ethnic Study of Atherosclerosis), 2,620 individuals were classified as low risk for CHD events (FRS

RESULTS: Mean follow-up was 2.5 years. CAC progression occurred in 574 participants (22% overall; 214 of 1,830 with baseline CAC = 0 and 360 of 790 with baseline CAC >0). Addition of various combinations of novel markers to the base model (c statistic = 0.711) revealed improvements in discrimination of approximately only 0.005 each (c statistics 0.7158, 0.7160, and 0.7164) for the best-fit models. All 3 best-fit novel marker models calibrated well but were similar to the base model in predicting individual risk probabilities for CAC progression. The highest prevalence of CAC progression occurred in the highest compared with the lowest probability quartile groups (39.2% to 40.3% vs. 6.4% to 7.1%).

CONCLUSIONS: In individuals at low predicted risk according to FRS, traditional risk factors predicted CAC progression in the short term with good discrimination and calibration. Prediction improved minimally when various novel markers were added to the model.

PMID:

Impact of Progression of Diastolic Dysfunction on Mortality in Patients With Normal Ejection Fraction

OBJECTIVES: Diastolic dysfunction is an independent predictor of mortality in patients with normal left ventricular ejection fraction. There are limited data, however, on whether worsening of diastolic function is associated with worse prognosis.

METHODS: We reviewed clinical records and echocardiograms of consecutive patients who had baseline echocardiograms between January 1, 2005, and December 31, 2009, that showed left ventricular ejection fraction ≥55% and who subsequently had a follow-up echocardiogram within 6 to 24 months. Diastolic function was labeled as normal, mild, moderate, or severe dysfunction. All-cause mortality was determined by use of the Social Security Death Index. Kaplan-Meier survival analysis and Cox regression analysis with a proportional hazard model were performed to assess outcomes.

RESULTS: A total of 1065 outpatients were identified (mean±SD age, 67.9±13.9 years; 58% male). Baseline diastolic dysfunction was present in 770 patients (72.3%), with mild being the most prevalent. On follow-up testing (mean±SD, 1.1±0.4 years), 783 patients (73%) had stable, 168 (16%) had worsening, and 114 (11%) had improved baseline diastolic function. Eighty-eight patients (8.3%) had a decrease in left ventricular ejection fraction to

CONCLUSIONS: In patients with normal baseline left ventricular ejection fraction, worsening of diastolic function is an independent predictor of mortality.

PMID:

Low-Flow, Low-Gradient Severe Aortic Stenosis Despite Normal Ejection Fraction Is Associated With Severe Left Ventricular Dysfunction as Assessed by Speckle-Tracking Echocardiography: A Multicenter Study

OBJECTIVES: Low-flow low-gradient (LFLG) is sometimes observed in severe aortic stenosis (AS) despite normal ejection fraction, but its frequency and mechanisms are still debated.  We aimed to describe the characteristics of patients with LFLG AS and assess the presence of longitudinal left ventricular dysfunction in these patients.

METHODS: In a multicenter prospective study, 340 consecutive patients with severe AS and normal ejection fraction were studied.  Longitudinal left ventricular function was assessed by 2D-strain and global afterload by valvulo-arterial impedance.  Patients were classified according to flow and gradient: low flow was defined as a stroke volume index ≤35 mL/m(2), low gradient as a mean gradient ≤40 mm Hg.

RESULTS: Most patients (n=258, 75.9%) presented with high-gradient AS, and 82 patients (24.1%) with low-gradient AS.  Among the latter, 52 (15.3%) presented with normal flow and low gradient and 30 (8.8%) with LFLG.  As compared with normal flow and low gradient, patients with LFLG had more severe AS (aortic valve area=0.7±0.12 cm(2) versus 0.86±0.14 cm(2)), higher valvulo-arterial impedance (5.5±1.1 versus 4±0.8 mm Hg/mL/m(2)), and worse longitudinal left ventricular function (basal longitudinal strain=-11.6±3.4 versus -14.8±3%; P<0.001 for all).

CONCLUSIONS: LFLG AS is observed in 9% of patients with severe AS and normal ejection fraction and is associated with high global afterload and reduced longitudinal systolic function.  Patients with normal-flow low-gradient AS are more frequent and present with less severe AS, normal afterload, and less severe longitudinal dysfunction.  Severe left ventricular longitudinal dysfunction is a new explanation to the concept of LFLG AS.

PMID: 22109983

Patient-Specific Simulations of Transcatheter Aortic Valve Stent Implantation

OBJECTIVES: Transcatheter aortic valve implantation (TAVI) enables treatment of aortic stenosis with no need for open heart surgery. According to current guidelines, only patients considered at high surgical risk can be treated with TAVI. In this study, patient-specific analyses were performed to explore the feasibility of TAVI in morphologies, which are currently borderline cases for a percutaneous approach.

METHODS: Five patients were recruited: four patients with failed bioprosthetic aortic valves (stenosis) and one patient with an incompetent, native aortic valve. Three-dimensional models of the implantation sites were reconstructed from computed tomography images. Within these realistic geometries, TAVI with an Edwards Sapien stent was simulated using finite element (FE) modelling. Engineering and clinical outcomes were assessed.

RESULTS: In all patients, FE analysis proved that TAVI was morphologically feasible. After the implantation, stress distribution showed no risks of immediate device failure and geometric orifice areas increased with low risk of obstruction of the coronary arteries. Maximum principal stresses in the arterial walls were higher in the model with native outflow tract.

CONCLUSIONS: FE analyses can both refine patient selection and characterise device mechanical performance in TAVI, overall impacting on procedural safety in the early introduction of percutaneous heart valve devices in new patient populations.

PMID: 22286953

Real-Time Magnetic Resonance Imaging-Guided Transarterial Aortic Valve Implantation In-Vivo Evaluation in Swine

Real-time magnetic resonance imaging (rtMRI) is considered attractive for guiding transarterial aortic valve implantation (TAVI). Compared with X-ray fluoroscopy, rtMRI offers unrestricted scan plane orientation and an unsurpassed soft-tissue contrast with simultaneous device visualization, potentially allowing enhanced positioning accuracy together with online monitoring of cardiac function and immediate detection of complications. Additionally, MRI offers noninvasive assessment of cardiovascular anatomy and function for preinterventional screening as well as immediate morphologic and functional assessment of the implanted prothesis and may, thus, be envisioned as a single comprehensive imaging modality for TAVI. We, therefore, sought to assess the preclinical feasibility of entirely rtMRI-guided TAVI in a swine model (female domestic pigs weighing 70.5 to 86.5 kg) using the original CoreValve (Medtronic, Minneapolis, Minnesota) prosthesis without alterations in conjunction with a modified, MRI-compatible delivery device (1).

rtMRI-guided transfemoral (n = 2) and transsubclavian (n = 6) TAVI was performed in a 1.5-T whole-body MRI scanner (Magnetom Avanto, Siemens Healthcare Sector, Erlangen, Germany). Conventional x-ray fluoroscopy and angiography were performed for comparison. After pre-interventional evaluation using standard steady-state free-precession imaging with electrocardiographic gating and time-resolved retrospective image reconstruction (cine-TrueFISP retro) (TR, 40 ms; TE, 1.1 ms; flip angle, 62°; FOV, 380 x 330 mm2; matrix, 192 x 168; slice thickness, 6 mm; bandwidth, 930 Hz/pixel; image acquisition time, 15 s for a single slice acquired over 20 phases of the cardiac R-R interval) and electrocardiography-triggered, flow-sensitive, phase-contrast sequences (TR, 62 ms; TE, 3.5 ms; flip angle, 30°; FOV, 320 x 220 mm2; matrix, 192 x 132; bandwidth, 555 Hz/pixel; acquisition time, 1 min 52 s; velocity encoding value, 100 cm/s), TAVI was performed using rtMRI fluoroscopy based on a commercially available interactive real-time projection reconstruction TrueFISP sequence with radial k-space filling during free breathing and without cardiac triggering that was modified to achieve a frame rate of 7 frames per second (TR, 3.0 ms; TE, 1.5 ms; flip angle, 70°; FOV, 360 x 360 mm2; matrix, 192 x 192; bandwidth, 1530 Hz/pixel; slice thickness, 6 mm). Images were displayed without delay inside the scanner room and could be adapted interactively according to the operator’s (P.K.) needs while the sequence was running. After TAVI, real-time TrueFISP, cine-TrueFISP retro, and flow-sensitive phase-contrast sequences were used to verify procedural success. Autopsies were performed to validate MRI findings.

Three-point localizer sequences allowed for rapid detection (11 ± 3 min) of all scan planes required for preinterventional evaluation, procedural guidance, and post-procedural validation. High-resolution TrueFISP retro sequences enabled detailed visualization of all procedurally relevant anatomic landmarks and allowed precise measurements (aortic annulus diameter in long axis, 17 ± 3 mm; aortic arch diameter, 21 ± 4 mm; distance from aortic annulus to left and right coronary ostium, 9 ± 3 and 10 ± 2 mm; access vessel diameter, 6.9 ± 1.2 mm) in good accordance with measurements on previous angiographic images (mean error, 0.4 ± 0.3 mm; p = NS) and during autopsy (mean error, 0.5 ± 0.2 mm; p = NS).

Passive device visualization using real-time TrueFISP sequences provided reliable imaging guidance during TAVI superior to fluoroscopy. Mild susceptibility artifacts confined to the loaded stent valve enabled adequate determination of the position of stent valve and delivery system in relation to the surrounding anatomy without undue image distortion, allowing a precise, real-time anatomic orientation during device navigation through the vasculature, aortic valve passage, positioning and deployment of the prosthesis, and catheter withdrawal.

In 6 of 8 animals, an oversized 26-mm CoreValve prosthesis was successfully placed across the aortic annulus without dislocation, coronary artery obstruction, or impairment of the mitral valve, as confirmed by autopsy (rtMRI acquisition time, 4 ± 2 min) (Fig. 1). However, 2 implant failures occurred. The first was a result of unsuccessful aortic arch passage due to insufficient support by the initially used MRI-compatible, soft polymer guidewire and led to a controlled deployment of the stent valve in the thoracic aorta, which is sometimes required in clinical application when the prosthesis dislocates into the ascending aorta during deployment. As a consequence, we continued our experiments without guidewire support and focused on the straighter transsubclavian access route. The second implant failure occurred due to perforation of the left ventricular apex caused by the delivery device, which was inadvertently pushed with too much force, this complication being immediately detected by rtMRI. Both cases indicate that rtMRI might improve both precision and safety of the TAVI procedure.

Postprocedural TrueFISP retro sequences allowed precise structural evaluation of the procedural result in good accordance with autopsy findings. Flow-sensitive, electrocardiography-triggered, phase-contrast sequences with imaging planes placed approximately 1 cm below and above the nitinol stent frame confirmed good systolic transvalvular blood flow without diastolic regurgitation. The current study demonstrates the preclinical feasibility of entirely MRI-guided TAVI. As a single imaging modality, MRI offered comprehensive diagnostic evaluation of the relevant cardiac and vascular anatomy for adequate interventional planning, real-time procedural guidance with excellent anatomic orientation, immediate evaluation of procedure-related complications, and post-interventional validation of treatment success with a total procedure time of 61 ± 13 min. Complementary to reduction of radiation exposure and nephrotoxic contrast media, rtMRI guidance, therefore, provides clinically relevant advantages over conventional X-ray-fluoroscopy and warrants further attention. These advantages should encourage future efforts to translate rtMRI-guided TAVI into clinical application using commercial but modified or entirely novel devices (2,3) and to overcome remaining obstacles such as the development of suitable, MRI-compatible guidewires.

PMID: 22222083